Thus, BCR-ABL1 TK inhibitors (TKIs) are the first-line therapy for most patients with CML, acting on the kinase domain by competing at the adenosine triphosphate (ATP)-binding site. This evidence concerns the gene TKT and chronic myelogenous leukemia, BCR-ABL1 positive.